- Home
- SIGA vs ANNX Comparison
SIGA vs ANNX Comparison
Compare SIGA & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- ANNX
- Stock Information
- Founded
- SIGA 1995
- ANNX 2011
- Country
- SIGA United States
- ANNX United States
- Employees
- SIGA N/A
- ANNX N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- ANNX Health Care
- Exchange
- SIGA Nasdaq
- ANNX Nasdaq
- Market Cap
- SIGA N/A
- ANNX 362.4M
- IPO Year
- SIGA 1997
- ANNX 2020
- Fundamental
- Price
- SIGA $5.49
- ANNX $1.82
- Analyst Decision
- SIGA
- ANNX Strong Buy
- Analyst Count
- SIGA 0
- ANNX 5
- Target Price
- SIGA N/A
- ANNX $18.67
- AVG Volume (30 Days)
- SIGA 441.3K
- ANNX 1.8M
- Earning Date
- SIGA 03-11-2025
- ANNX 05-12-2025
- Dividend Yield
- SIGA 10.95%
- ANNX N/A
- EPS Growth
- SIGA N/A
- ANNX N/A
- EPS
- SIGA 0.82
- ANNX N/A
- Revenue
- SIGA $138,719,350.00
- ANNX N/A
- Revenue This Year
- SIGA $35.56
- ANNX N/A
- Revenue Next Year
- SIGA N/A
- ANNX N/A
- P/E Ratio
- SIGA $6.68
- ANNX N/A
- Revenue Growth
- SIGA N/A
- ANNX N/A
- 52 Week Low
- SIGA $5.16
- ANNX $1.76
- 52 Week High
- SIGA $12.83
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- SIGA 42.19
- ANNX 29.68
- Support Level
- SIGA $5.55
- ANNX $2.18
- Resistance Level
- SIGA $6.04
- ANNX $2.75
- Average True Range (ATR)
- SIGA 0.24
- ANNX 0.24
- MACD
- SIGA -0.01
- ANNX -0.03
- Stochastic Oscillator
- SIGA 14.49
- ANNX 3.02
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.